Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Ga-68 Somatostatin Receptor PET/CT in von Hippel-Lindau Disease

Ga-68 Somatostatin Receptor PET/CT in von Hippel-Lindau Disease Von Hippel-Lindau (VHL) disease is a dominantly inherited familial cancer syndrome with a variety of benign and malignant tumors such as retinal and central nervous system hemangioblastomas, endolymphatic sac tumors, renal cysts and tumors, pancreatic cysts and tumors, pheochromocytomas, and epididymal cystadenomas. Cross-sectional modalities (computed tomography and magnetic resonance imaging) as well as ultrasound play a major role in the initial evaluation and follow-up of the various manifestations of VHL disease. Ga-68-labeled somatostatin receptor analogs already have a significant role in the diagnosis, staging, and therapy management of neuroendocrine neoplasms and neural crest tumors. Herein, we report a case presenting a variety of malignancies in VHL and showing the usefulness of Ga-68 somatostatin receptor PET/CT as a one-stop-shop imaging modality in the management of VHL disease. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Nuclear Medicine and Molecular Imaging Springer Journals

Loading next page...
 
/lp/springer-journals/ga-68-somatostatin-receptor-pet-ct-in-von-hippel-lindau-disease-xAojE9gcDV

References (17)

Publisher
Springer Journals
Copyright
Copyright © 2012 by Korean Society of Nuclear Medicine
Subject
Medicine & Public Health; Cardiology; Nuclear Medicine; Oncology; Orthopedics; Imaging / Radiology
ISSN
1869-3474
eISSN
1869-3482
DOI
10.1007/s13139-012-0133-0
pmid
24900047
Publisher site
See Article on Publisher Site

Abstract

Von Hippel-Lindau (VHL) disease is a dominantly inherited familial cancer syndrome with a variety of benign and malignant tumors such as retinal and central nervous system hemangioblastomas, endolymphatic sac tumors, renal cysts and tumors, pancreatic cysts and tumors, pheochromocytomas, and epididymal cystadenomas. Cross-sectional modalities (computed tomography and magnetic resonance imaging) as well as ultrasound play a major role in the initial evaluation and follow-up of the various manifestations of VHL disease. Ga-68-labeled somatostatin receptor analogs already have a significant role in the diagnosis, staging, and therapy management of neuroendocrine neoplasms and neural crest tumors. Herein, we report a case presenting a variety of malignancies in VHL and showing the usefulness of Ga-68 somatostatin receptor PET/CT as a one-stop-shop imaging modality in the management of VHL disease.

Journal

Nuclear Medicine and Molecular ImagingSpringer Journals

Published: Apr 27, 2012

There are no references for this article.